Skip to content

Navigation

User login

Follow us!

Home

Feed aggregator

IMap Celebration: Calls

Institute for Healthcare Improvement - Fri, 08/13/2010 - 15:24
Short Description (Required)

ChrisHartman: Prolatis’: Undeclared Drug Ingredient http://bit.ly/ds6pvJ

Twitter Feed - Fri, 08/13/2010 - 14:01
ChrisHartman: Prolatis’: Undeclared Drug Ingredient http://bit.ly/ds6pvJ

Prolatis’: Undeclared Drug Ingredient

FDA MedWatch - Fri, 08/13/2010 - 13:55
Product marketed as dietary supplement contains undeclared sulfoaildenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.

ChrisHartman: Lamictal (lamotrigine): Label Change - Risk of Aseptic Meningitis http://bit.ly/a14zHy

Twitter Feed - Thu, 08/12/2010 - 19:31
ChrisHartman: Lamictal (lamotrigine): Label Change - Risk of Aseptic Meningitis http://bit.ly/a14zHy

Lamictal (lamotrigine): Label Change - Risk of Aseptic Meningitis

FDA MedWatch - Thu, 08/12/2010 - 19:14
Warnings and Precautions section of Prescribing Information and patient Medication Guide revised to include information about the risk of aseptic meningitis.

ChrisHartman: Novacare LLC Products: Recall - Undeclared Drug Ingredient http://bit.ly/aprYNi

Twitter Feed - Wed, 08/11/2010 - 19:31
ChrisHartman: Novacare LLC Products: Recall - Undeclared Drug Ingredient http://bit.ly/aprYNi

Novacare LLC Products: Recall - Undeclared Drug Ingredient

FDA MedWatch - Wed, 08/11/2010 - 18:00
Products marketed as dietary supplement sexual enhancers for men contain undeclared sulfoaildenafil, which may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels.

Diffusing Aviation Innovations in a Hospital in the Netherlands

Journal on Quality and Patient Safety - Mon, 08/09/2010 - 20:57
Joint Commission Journal on Quality and Patient Safety, Vol. 36, No. 8., pp. 339-347.
Dirk de Korne, Jeroen van Wijngaarden, Frans Hiddema, Fred Bleeker, Peter Pronovost, Niek Klazinga

Risk Assessing Risk Assessment

Journal on Quality and Patient Safety - Mon, 08/09/2010 - 20:57
Joint Commission Journal on Quality and Patient Safety, Vol. 36, No. 8., pp. 348-350.
Richard Croteau

A Practical Guide to Failure Mode and Effects Analysis in Health Care: Making the Most of the Team and Its Meetings

Journal on Quality and Patient Safety - Mon, 08/09/2010 - 20:57
Joint Commission Journal on Quality and Patient Safety, Vol. 36, No. 8., pp. 351-358.
Laura Ashley, Gerry Armitage, Maria Neary, Gillian Hollingsworth

Reducing Errors During Patient-Controlled Analgesia Therapy Through Failure Mode and Effects Analysis

Journal on Quality and Patient Safety - Mon, 08/09/2010 - 20:57
Joint Commission Journal on Quality and Patient Safety, Vol. 36, No. 8., pp. 359-364.
Janet Moss

Three Kinds of Proactive Risk Analyses for Health Care

Journal on Quality and Patient Safety - Mon, 08/09/2010 - 20:57
Joint Commission Journal on Quality and Patient Safety, Vol. 36, No. 8., pp. 365-375.
Garill Coles, Becky Fuller, Kathleen Nordquist, Steve Weissenberger, Leann Anderson, Brooke DuBois

Involving Intensive Care Unit Nurses in a Proactive Risk Assessment of the Medication Management Process

Journal on Quality and Patient Safety - Mon, 08/09/2010 - 20:57
Joint Commission Journal on Quality and Patient Safety, Vol. 36, No. 8., pp. 376-385.
Helene Faye, Joy Rivera-Rodriguez, Ben-Tzion Karsh, Ann Schoofs Hundt, Christine Baker, Pascale Carayon

ChrisHartman: Combat Application Tourniquets (C-A-T): Suspected Counterfeit Product http://bit.ly/cQU76a

Twitter Feed - Mon, 08/09/2010 - 19:31
ChrisHartman: Combat Application Tourniquets (C-A-T): Suspected Counterfeit Product http://bit.ly/cQU76a

Combat Application Tourniquets (C-A-T): Suspected Counterfeit Product

FDA MedWatch - Mon, 08/09/2010 - 17:30
Suspected counterfeit product is weaker, and breaks or bends before necessary force can be applied to stop blood flow. Excessive blood loss can endanger the victim’s life and ultimately lead to death.

ChrisHartman: Inferior Vena Cava (IVC) Filters: Initial Communication: Risk of Adverse Events with Long Term Use http://bit.ly/d5ghQY

Twitter Feed - Mon, 08/09/2010 - 15:31
ChrisHartman: Inferior Vena Cava (IVC) Filters: Initial Communication: Risk of Adverse Events with Long Term Use http://bit.ly/d5ghQY

Inferior Vena Cava (IVC) Filters: Initial Communication: Risk of Adverse Events with Long Term Use

FDA MedWatch - Mon, 08/09/2010 - 15:20
Known long term risks associated with IVC filters include lower limb deep vein thrombosis, filter fracture, filter migration, filter embolization and IVC perforation.

ChrisHartman: Solo Slim, Solo Slim Extra Strength: Recall - Undeclared Drug Ingredient http://bit.ly/bH0uIs

Twitter Feed - Mon, 08/09/2010 - 14:01
ChrisHartman: Solo Slim, Solo Slim Extra Strength: Recall - Undeclared Drug Ingredient http://bit.ly/bH0uIs

ChrisHartman: Revivexxx Extra Strength: Recall - Undeclared Drug Ingredient http://bit.ly/cZqi4N

Twitter Feed - Mon, 08/09/2010 - 14:01
ChrisHartman: Revivexxx Extra Strength: Recall - Undeclared Drug Ingredient http://bit.ly/cZqi4N

Solo Slim, Solo Slim Extra Strength: Recall - Undeclared Drug Ingredient

FDA MedWatch - Mon, 08/09/2010 - 13:25
Product contains undeclared didesmethyl sibutramine, which may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.
AdaptiveThemes